Activity Program During Aromatase Inhibitor Therapy

Status Completed

Clinical Trial Summary

The primary aim of the trial is to investigate if a simple outdoor walking intervention, which is practicable under real-life conditions, beginning at the start of adjuvant aromatase inhibitor (AI) therapy, can prevent the occurrence of muscle or joint pain/stiffness in breast cancer patients.

Clinical Trial Description

After tumor removal, patients with hormone receptor positive breast cancer tumors often receive adjuvant endocrine treatment, with the use of an aromatase inhibitor (AI) being standard of care in the population of postmenopausal women. Common side effects of AI therapy are joint pain, muscle pain, stiffness, fatigue, hot flashes, and weight gain. Arthralgia and/or myalgia can result in lower physical activity and can negatively influence quality of life (QoL). In addition, muscle or joint pain/stiffness are among the main reasons for non-compliance and discontinuation of AI therapy. Because AI therapy is usually administered for 5 and sometimes even 10 years, this is a major clinical challenge. For breast cancer patients undergoing AI therapy, physical activity can provide potential benefit by reducing muscle/joint pain and fatigue and can thus improve QoL. The preventive effect of physical activity on AI side effects, however, remains elusive. In addition, activity programs to reduce AI side effects have so far mostly been rather complex. The primary aim of the trial is to investigate if a simple outdoor walking intervention, which is practicable under real-life conditions, beginning at the start of adjuvant AI therapy, can prevent the occurrence of muscle or joint pain/stiffness in breast cancer patients. Furthermore, this trial will assess the effect of physical activity on symptom burden in general and quality of life in patients receiving adjuvant AI therapy. During the follow-up phase, the trial will assess whether this intervention leads to a sustained change in lifestyle regarding activity, less pain, and better treatment adherence in the intervention group. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03786198
Study type	Interventional
Source	Swiss Group for Clinical Cancer Research
Contact
Status	Completed
Phase	N/A
Start date	March 28, 2019
Completion date	June 8, 2023

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04538833` - GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel	Phase 2
Completed	`NCT04436744` - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)	Phase 2
Completed	`NCT02187744` - A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)	Phase 3
Terminated	`NCT01155063` - Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients	N/A
Recruiting	`NCT03949634` - Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)	Phase 3
Active, not recruiting	`NCT05730647` - Prospective Observational Study of Adjuvant Hormone Treatment in Estrogen-receptor Positive Premenopausal Early Breast Cancer Patients
Terminated	`NCT01919229` - A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)	Phase 2
Active, not recruiting	`NCT04293393` - Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients	Phase 2
Completed	`NCT00713141` - Evaluation of Brain Function Before and After Standard Chemotherapy for Early Breast Cancer	N/A
Recruiting	`NCT06341894` - Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer	Phase 2
Not yet recruiting	`NCT06404736` - QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer	Phase 2
Not yet recruiting	`NCT06404463` - QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer	Phase 2
Not yet recruiting	`NCT06435104` - Aromatherapy in the Treatment of Early Breast Cancer	Phase 2
Recruiting	`NCT03520894` - Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer	N/A
Completed	`NCT01613352` - Feasibility of Ambulatory Surgery for Early Breast Cancer	N/A
Completed	`NCT02738970` - A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)	Phase 1
Recruiting	`NCT01792726` - A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.	N/A
Completed	`NCT00323479` - Arthralgia During Anastrozole Therapy for Breast Cancer	Phase 4
Completed	`NCT03493854` - A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer	Phase 3
Recruiting	`NCT04291378` - The DBCG Proton Trial: Photon Versus Proton Radiation Therapy for Early Breast Cancer	N/A